Rallybio Ipa, LLC

Prophylix Pharma As

Bjorn Ragnar Skogen

Anne Husebekk

Terje Michaelsen

Oistein Ihle

Tor Brynjar Stuge

Heidi Tiller

Mariana Eksteen

Jens Kjeldsen-Kragh

Mette Kjaer

Anne Husse-Bekk

Mette Kjaer Killie

Provided is an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Antibodies against HPA-1a

The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA 1a within 72 hours after delivery in the first non-compatible pregnancy.

Preparation useful for, and method for treatment of neonatal alloimmune thrombocytopenia (NAIT)

A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA1a within 72 hours after delivery in the first non-compatible pregnancy.

Growing community of inventors

Tromso, Norway

Bjorn Ragnar Skogen